For example, a case-control study including 76 patients and 30 healthy age- and sex-matched controls reported that the median serum levels of IL-17 in patients with stomach cancer were higher than those of controls (9.04 vs. 8.07 pg/ml, P=0.010), but serum IL-17 levels were not associated with tumor stage (small (1-2 stage) vs. large (3-4 stage): 9.20 vs. 8.27 pg/ml, P=0.410) (35). The gene discussed is IL17A; the disease is gastric neoplasm.